Manages hypertension. ANDA 217293, held by Ajanta Pharma Ltd. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 217293 (Guanfacine Hydrochloride), held by Ajanta Pharma Ltd, was first approved by FDA on Apr 27, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Guanfacine tablets, USP are indicated in the management of hypertension. Guanfacine tablets, USP may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 27, 2023 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters